Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant
© 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology..
Hepatitis B virus (HBV) reactivation can occur with the use of immunosuppressive therapy used to treat autoimmune conditions, such as rheumatoid arthritis. Janus kinase inhibitors, such as upadacitinib, have been approved for the treatment of rheumatoid arthritis. This is the first case report of a patient who used upadacitinib without antiviral prophylaxis against HBV and developed HBV reactivation, leading to fulminant hepatic failure necessitating emergent liver transplantation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
ACG case reports journal - 11(2024), 4 vom: 28. Apr., Seite e01327 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khan, Sarosh Ahmed [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 09.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.14309/crj.0000000000001327 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM37076241X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37076241X | ||
| 003 | DE-627 | ||
| 005 | 20240409233039.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240408s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14309/crj.0000000000001327 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM37076241X | ||
| 035 | |a (NLM)38586821 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khan, Sarosh Ahmed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. | ||
| 520 | |a Hepatitis B virus (HBV) reactivation can occur with the use of immunosuppressive therapy used to treat autoimmune conditions, such as rheumatoid arthritis. Janus kinase inhibitors, such as upadacitinib, have been approved for the treatment of rheumatoid arthritis. This is the first case report of a patient who used upadacitinib without antiviral prophylaxis against HBV and developed HBV reactivation, leading to fulminant hepatic failure necessitating emergent liver transplantation | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Janus kinase (JAK) inhibitors, | |
| 650 | 4 | |a hepatitis B reactivation, | |
| 650 | 4 | |a hepatitis B virus (HBV), | |
| 650 | 4 | |a liver failure, | |
| 650 | 4 | |a liver transplant | |
| 650 | 4 | |a upadacitinib, | |
| 700 | 1 | |a Zahid, Rida |e verfasserin |4 aut | |
| 700 | 1 | |a Amir, Muhammad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACG case reports journal |d 2013 |g 11(2024), 4 vom: 28. Apr., Seite e01327 |w (DE-627)NLM245263268 |x 2326-3253 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g number:4 |g day:28 |g month:04 |g pages:e01327 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.14309/crj.0000000000001327 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 |e 4 |b 28 |c 04 |h e01327 | ||